Absci to Participate in Upcoming Investor Conferences
Absci to Participate in Upcoming Investor Conferences
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
2024年8月21日，Absci公司（納斯達克股票代碼：ABSI）作爲以數據爲先的生成式人工智能藥物研發公司，宣佈將參加以下即將舉行的投資者會議。
-
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat on Thursday, September 5th at 5:35 p.m. Eastern Time
- 摩根士丹利第22屆全球醫療保健大會
於2024年9月5日下午5:35在東部時間進行的閒聊
-
Citi 2024 Global TMT Conference
Fireside chat on Friday, September 6th at 8:20 a.m. Eastern Time
- 花旗銀行2024年全球技術、媒體和電信大會
於2024年9月6日上午8:20在東部時間進行的閒聊
-
H.C. Wainwright 26th Annual Global Investment Conference
Fireside chat on Tuesday, September 10th at 12:00 p.m. Eastern Time
- 漢肯萊特第26屆全球投資大會
於2024年9月10日下午12:00在東部時間進行的閒聊
Interested parties may access live and archived webcasts of these events on the company's investor relations website at: investors.absci.com.
有興趣的各方可以在公司投資者關係網站上訪問這些事件的直播和存檔網絡廣播。 investors.absci.com.
About Absci
關於Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci是一家將人工智能與可擴展實驗室技術相結合的數據導向的生成AI藥物研發公司，旨在更快地爲患者創建更好的生物製品。我們的綜合藥物創新平台通過同時優化開發和治療效益的多個藥物特性，釋放加速臨床時間並增加成功率的潛力。憑藉訓練數據、人工智能和溼實驗驗證，我們可以每週篩選數十億個細胞，從AI設計的抗體到溼實驗驗證的候選藥物只需短短六週。Absci的總部位於華盛頓溫哥華市，AI研究實驗室位於紐約市，創新中心位於瑞士楚格。 該平台通過同時優化多種對開發和治療效果都重要的藥物特性，釋放了加速臨床時間並增加成功概率的潛力。憑藉訓練數據、人工智能的創造力以及溼實驗室的驗證能力，我們每週可以篩選數十億個細胞，使我們能夠在短短六週內從人工智能設計的候選者轉化爲溼實驗室驗證的候選者。Absci總部位於華盛頓溫哥華，我們的人工智能研究實驗室位於紐約市，創新中心位於瑞士祖格。歡迎訪問 ，以及 Twitter(@Abscibio)@absci，以及 Twitter(@Abscibio)@Abscibio）以及YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投資者聯繫方式
Alex Khan
財務與投資者關係副總裁
investors@absci.com
Media Contact
press@absci.com
媒體聯繫人
press@absci.com
譯文內容由第三人軟體翻譯。
